Updating results

94 results

Sort: Relevance | Date

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Gout

Proposed [GID-QS10100] Expected publication date: TBC

Quality standard Proposed

Housing: planning to improve health and wellbeing

Proposed [GID-QS10117] Expected publication date: TBC

Quality standard Proposed

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Pernicious Anaemia

Proposed [GID-QS10130] Expected publication date: TBC

Quality standard Proposed

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

Proposed [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance Proposed

Gambling

Proposed [GID-QS10099] Expected publication date: TBC

Quality standard Proposed

Secondary care management of malignant hypertension

Proposed [GID-QS10107] Expected publication date: TBC

Quality standard Proposed

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Proposed [GID-QS10106] Expected publication date: TBC

Quality standard Proposed

Blood transfusion in neonatology

Proposed [GID-QS10098] Expected publication date: TBC

Quality standard Proposed

Nutrition in hospital

Proposed [GID-QS10104] Expected publication date: TBC

Quality standard Proposed

Parenteral nutrition in neonates

Proposed [GID-QS10087] Expected publication date: TBC

Quality standard Proposed

Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive sleepiness caused by narcolepsy or obstructive sleep apnoea [ID1499]

Proposed [GID-TA10430] Expected publication date: TBC

Technology appraisal guidance Proposed

Depression in adults (update)

Proposed [GID-QS10057] Expected publication date: TBC

Quality standard Proposed

Prevention and non-surgical treatment of pelvic floor failure/incompetence/prolapse

Proposed [GID-QS10129] Expected publication date: TBC

Quality standard Proposed

Fostamatinib for treating chronic immune thrombocytopenic purpura [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Technology appraisal guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing migraine [ID1372]

Proposed [GID-TA10454] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Proposed [GID-TA10457] Expected publication date: TBC

Technology appraisal guidance Proposed

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Proposed [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance Proposed

Midostaurin for treating advanced systemic mastocytosis ID1573

Proposed [GID-TA10503] Expected publication date: TBC

Technology appraisal guidance Proposed

Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: TBC

Technology appraisal guidance Proposed

Brolucizumab for treating wet age-related macular degeneration [ID1254]

Proposed [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance Proposed

Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

Proposed [GID-TA10450] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Proposed [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Esketamine for treatment-resistant depression (ID1414)

Proposed [GID-TA10371] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Zynteglo for treating transfusion-dependent beta-thalassaemia ID968

Proposed [GID-TA10334] Expected publication date: 24 June 2020

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: TBC

Technology appraisal guidance Proposed

Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

Proposed [GID-TA10507] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab for previously treated squamous non-small-cell lung cancer ID1559

Proposed [GID-TA10516] Expected publication date: TBC

Technology appraisal guidance Proposed